Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Absorption, Metabolism, and Excretion of 14C-Lazertinib in Healthy Males
NCT04410081Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jul 2020
- Primary completion
- Mar 2021
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of lazertinib in non-small cell lung cancer (NSCLC), sponsored by Janssen Pharmaceutical. Primary endpoints: Maximum Observed Plasma Concentration up to 99 days, Time to Reach Maximum Observed Plasma Concentration up to 99 days and 8 more. Started Jul 2020; status: completed.
02
Drugs
lazertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04410081.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04410081.